Lilly makes steady progress in non-covalent BTK inhibition
Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.
Phase 1 entrants seek improved safety
First-in-human clinical trial initiations include yet another KRAS G12C inhibitor, and an ADC against PD-L1.
Novartis goes 0 for 2 in PD-1 blockade
BeiGene regains rights to tislelizumab as another oncology asset blows up for Novartis.
Another twist in the TIGIT saga
A statistical analysis of Skyscraper-01’s second interim read is inadvertently posted on a Roche website.
Not the sort of Revolution that EQRX had dreamt of
EQRX had once hoped to disrupt cosy US cancer drug pricing arrangements, but when that model failed the group found that cash was its best asset.
